$RFL 8-K/A SEC Filings

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Poten...

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

On March 25, 2025, Rafael Holdings, Inc. (“Rafael” or the “Company”), Cyclo Therapeutics, Inc. (“Cyclo”), Tandem Therapeutics, Inc., a wholly-owned subsidiary of the Company (“First Merger Sub”), and Tandem Therapeutics, LLC, a wholly-ow...

On March 13, 2024, Rafael Holdings, Inc. (“Rafael”, “Parent”, or the “Company”), Cornerstone Pharmaceuticals, Inc. (“Cornerstone”), and other holders of debt and equity securities of Cornerstone agreed to various transactions which effec...

On August 1, 2023, Rafael Holdings, Inc. (the “Company”) purchased 4,000,000 shares of common stock (the “Shares”) of Cyclo Therapeutics, Inc., a Nevada corporation (“Cyclo”), and a warrant to purchase an additional 4,000,000 Shares (the...

The following unaudited pro forma consolidated financial statements have been prepared to provide pro forma information with regard to a real estate disposition. The unaudited pro forma consolidated financial statements should be read in...

As previously disclosed on a Current Report on Form 8-K filed by Rafael Holdings, Inc. (the “Company”), on February 18, 2022, Broad Atlantic Associates LLC (the “Seller”), a subsidiary of the Company, entered into a Contract of Sale with...